Smith & Nephew SNATS (SNN)
(Delayed Data from NYSE)
$30.12 USD
-0.21 (-0.69%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $30.11 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$30.12 USD
-0.21 (-0.69%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $30.11 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum A VGM
Zacks News
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
by Zacks Equity Research
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
by Zacks Equity Research
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
by Zacks Equity Research
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care
by Zacks Equity Research
Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
by Zacks Equity Research
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
by Zacks Equity Research
Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
by Zacks Equity Research
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.
Smith+Nephew (SNN) Expands in Australia With New Alliance
by Zacks Equity Research
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
by Zacks Equity Research
Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew (SNN) New Buyout Expands Sports Medicine Suite
by Zacks Equity Research
Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.
The Zacks Analyst Blog Highlights Abbott Laboratories, Koninklijke Philips and Smith & Nephew
by Zacks Equity Research
Abbott Laboratories, Koninklijke Philips and Smith & Nephew are included in this Analyst Blog.
3 Medical Product Stocks With Solid Dividend Yield: ABT & Others
by Indrajit Bandyopadhyay
Here we pick three stocks, Abbott Laboratories (ABT), Koninklijke Philips (PHG) and Smith & Nephew SNATS (SNN) from the Medical - Products industry, with a solid five-year dividend growth history.
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Koninklijke Philips (PHG) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew (SNN) Loses -5.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Smith & Nephew (SNN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew's (SNN) CIT Technology Favored by New Study
by Zacks Equity Research
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Smith & Nephew (SNN) Simplifies ACL Surgery With New Offers
by Zacks Equity Research
Smith & Nephew (SNN) introduces QUADTRAC System and broadens ULTRABUTTON Adjustable Fixation Devices portfolio for ACL reconstruction.
Should Value Investors Buy National Vision (EYE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.